INKON Life Technology Co Ltd

Yingkang Life released its 2026 interim report, with net profit attributable to the parent company of 67.3959 million yuan. The company's total operating revenue was 1.016 billion yuan, and net cash inflow from operating activities was 286 million yuan. The latest asset-liability ratio was 38.91 percent, up 2.42 percentage points from the previous quarter and up 1.10 percentage points from the same period last year. The company's latest gross margin was 28.35 percent, latest return on equity was 2.83 percent, and diluted earnings per share was 0.07 yuan.

On the morning of July 27, A-share brain-computer interface concept stocks broke out strongly, with stocks in the sector rising collectively during the session. Chuangxin Medical hit a three-day two-board pattern, Aipeng Medical recorded a 20 percent daily limit up, Hainan Haiyao recorded a 10 percent daily limit up and hit a four-day two-board pattern, while Meihao Medical, New Journey, Yingkang Life, Xiangyu Medical, and Sanbo Brain Hospital and other concept stocks followed the rally. On the news front, a Chinese research team recently released a new type of EEG signal acquisition device, achieving for the first time globally the synchronous collection of EEG signals from over a thousand people across different regions. This breakthrough marks a key step forward in neural large model training and general brain-computer interface technology research and development. Kaiyuan Securities stated that it remains bullish on innovative drugs and their industry chain, as well as national strategic emerging industries such as AI, brain-computer interfaces, and biomanufacturing.

Yingkang Life disclosed an announcement that it plans to use its own funds to repurchase part of the company's shares through centralized bidding, for cancellation and reduction of registered capital. The repurchase amount will be no less than 30 million yuan and no more than 60 million yuan, with a repurchase price not exceeding 10 yuan per share. This repurchase is based on confidence in the company's future development and recognition of the company's value, aiming to safeguard shareholder interests and enhance investor confidence.